FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205877886> ?p ?o ?g. }

• W3205877886 endingPage "1670" @default.
• W3205877886 startingPage "1661" @default.
• W3205877886 abstract "Thrombotic antiphospholipid syndrome (TAPS) is characterized by venous, arterial, or microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin has historically been the standard treatment. Apixaban is an oral factor Xa inhibitor anticoagulant that requires no dose adjustment or monitoring. The efficacy and safety of apixaban compared with warfarin for TAPS patients remain unknown. This multicenter prospective randomized open-label blinded endpoint study assigned anticoagulated TAPS patients to apixaban or warfarin (target international normalized ratio 2-3) for 12 months. The primary efficacy outcome was clinically overt thrombosis and vascular death. Apixaban was first given at 2.5 mg twice daily. Two protocol changes were instituted based on recommendations from the data safety monitoring board. After the twenty-fifth patient was randomized, the apixaban dose was increased to 5 mg twice daily, and after the thirtieth patient was randomized, subjects with prior arterial thrombosis were excluded. Primary outcomes were adjudicated by independent experts blinded to treatment allocation. Patients randomized between 23 February 2015 and 7 March 2019 to apixaban (n = 23) or warfarin (n = 25) were similar. Among the components of the primary efficacy outcome, only stroke occurred in 6 of 23 patients randomized to apixaban compared with 0 of 25 patients randomized to warfarin. The study ended prematurely after the forty-eighth patient was enrolled. Conclusions from our study are limited due to protocol modifications and low patient accrual. Despite these limitations, our results suggest that apixaban may not be routinely substituted for warfarin to prevent recurrent thrombosis (especially strokes) among patients with TAPS. This trial was registered at www.clinicaltrials.gov as #NCT02295475." @default.
• W3205877886 created "2021-10-25" @default.
• W3205877886 creator A5007461026 @default.
• W3205877886 creator A5008016626 @default.
• W3205877886 creator A5013862976 @default.
• W3205877886 creator A5015413123 @default.
• W3205877886 creator A5018399608 @default.
• W3205877886 creator A5033748408 @default.
• W3205877886 creator A5037630109 @default.
• W3205877886 creator A5042560186 @default.
• W3205877886 creator A5049724325 @default.
• W3205877886 creator A5055898876 @default.
• W3205877886 creator A5065053305 @default.
• W3205877886 creator A5070196840 @default.
• W3205877886 date "2022-03-14" @default.
• W3205877886 modified "2023-10-17" @default.
• W3205877886 title "Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial" @default.
• W3205877886 cites W1586488555 @default.
• W3205877886 cites W2018856451 @default.
• W3205877886 cites W2027467473 @default.
• W3205877886 cites W2053081517 @default.
• W3205877886 cites W2054330426 @default.
• W3205877886 cites W2120492526 @default.
• W3205877886 cites W2132103149 @default.
• W3205877886 cites W2139785591 @default.
• W3205877886 cites W2146977059 @default.
• W3205877886 cites W2160597832 @default.
• W3205877886 cites W2162508946 @default.
• W3205877886 cites W2166402206 @default.
• W3205877886 cites W2265334376 @default.
• W3205877886 cites W2373145147 @default.
• W3205877886 cites W2514539105 @default.
• W3205877886 cites W2728054236 @default.
• W3205877886 cites W2755136792 @default.
• W3205877886 cites W2813643485 @default.
• W3205877886 cites W2946160313 @default.
• W3205877886 cites W2980869818 @default.
• W3205877886 cites W2999795829 @default.
• W3205877886 cites W3013809005 @default.
• W3205877886 cites W3082829636 @default.
• W3205877886 cites W3093717527 @default.
• W3205877886 doi "https://doi.org/10.1182/bloodadvances.2021005808" @default.
• W3205877886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34662890" @default.
• W3205877886 hasPublicationYear "2022" @default.
• W3205877886 type Work @default.
• W3205877886 sameAs 3205877886 @default.
• W3205877886 citedByCount "42" @default.
• W3205877886 countsByYear W32058778862021 @default.
• W3205877886 countsByYear W32058778862022 @default.
• W3205877886 countsByYear W32058778862023 @default.
• W3205877886 crossrefType "journal-article" @default.
• W3205877886 hasAuthorship W3205877886A5007461026 @default.
• W3205877886 hasAuthorship W3205877886A5008016626 @default.
• W3205877886 hasAuthorship W3205877886A5013862976 @default.
• W3205877886 hasAuthorship W3205877886A5015413123 @default.
• W3205877886 hasAuthorship W3205877886A5018399608 @default.
• W3205877886 hasAuthorship W3205877886A5033748408 @default.
• W3205877886 hasAuthorship W3205877886A5037630109 @default.
• W3205877886 hasAuthorship W3205877886A5042560186 @default.
• W3205877886 hasAuthorship W3205877886A5049724325 @default.
• W3205877886 hasAuthorship W3205877886A5055898876 @default.
• W3205877886 hasAuthorship W3205877886A5065053305 @default.
• W3205877886 hasAuthorship W3205877886A5070196840 @default.
• W3205877886 hasBestOaLocation W32058778861 @default.
• W3205877886 hasConcept C126322002 @default.
• W3205877886 hasConcept C127413603 @default.
• W3205877886 hasConcept C141071460 @default.
• W3205877886 hasConcept C168563851 @default.
• W3205877886 hasConcept C203092338 @default.
• W3205877886 hasConcept C2776301958 @default.
• W3205877886 hasConcept C2778205648 @default.
• W3205877886 hasConcept C2778661090 @default.
• W3205877886 hasConcept C2779161974 @default.
• W3205877886 hasConcept C2780638905 @default.
• W3205877886 hasConcept C2780645631 @default.
• W3205877886 hasConcept C2780868729 @default.
• W3205877886 hasConcept C71924100 @default.
• W3205877886 hasConcept C78519656 @default.
• W3205877886 hasConceptScore W3205877886C126322002 @default.
• W3205877886 hasConceptScore W3205877886C127413603 @default.
• W3205877886 hasConceptScore W3205877886C141071460 @default.
• W3205877886 hasConceptScore W3205877886C168563851 @default.
• W3205877886 hasConceptScore W3205877886C203092338 @default.
• W3205877886 hasConceptScore W3205877886C2776301958 @default.
• W3205877886 hasConceptScore W3205877886C2778205648 @default.
• W3205877886 hasConceptScore W3205877886C2778661090 @default.
• W3205877886 hasConceptScore W3205877886C2779161974 @default.
• W3205877886 hasConceptScore W3205877886C2780638905 @default.
• W3205877886 hasConceptScore W3205877886C2780645631 @default.
• W3205877886 hasConceptScore W3205877886C2780868729 @default.
• W3205877886 hasConceptScore W3205877886C71924100 @default.
• W3205877886 hasConceptScore W3205877886C78519656 @default.
• W3205877886 hasIssue "6" @default.
• W3205877886 hasLocation W32058778861 @default.
• W3205877886 hasLocation W32058778862 @default.
• W3205877886 hasLocation W32058778863 @default.
• W3205877886 hasOpenAccess W3205877886 @default.
• W3205877886 hasPrimaryLocation W32058778861 @default.

• next